In summary, our findings provide new insights about therapeutic approaches in Ph-like B-ALL with ABL-class alterations and a new cellular tool with which to study the biology of this high-risk leukemia subtype. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.